243 related articles for article (PubMed ID: 17691918)
1. Overlapping ligand specificity of P-glycoprotein and serum alpha(1)-acid glycoprotein: evidences and potential implications.
Zsila F
Curr Drug Metab; 2007 Aug; 8(6):563-93. PubMed ID: 17691918
[TBL] [Abstract][Full Text] [Related]
2. P-glycoprotein--implications of metabolism of neoplastic cells and cancer therapy.
Breier A; Barancík M; Sulová Z; Uhrík B
Curr Cancer Drug Targets; 2005 Sep; 5(6):457-68. PubMed ID: 16178819
[TBL] [Abstract][Full Text] [Related]
3. Homology Modeling of the Human P-glycoprotein (ABCB1) and Insights into Ligand Binding through Molecular Docking Studies.
Mora Lagares L; Minovski N; Caballero Alfonso AY; Benfenati E; Wellens S; Culot M; Gosselet F; Novič M
Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32517082
[TBL] [Abstract][Full Text] [Related]
4. N-(p-azido-3-[125I]iodophenethyl)spiperone binds to specific regions of P-glycoprotein and another multidrug binding protein, spiperophilin, in human neuroblastoma cells.
Safa AR; Agresti M; Bryk D; Tamai I
Biochemistry; 1994 Jan; 33(1):256-65. PubMed ID: 7904476
[TBL] [Abstract][Full Text] [Related]
5. Emerging significance of flavonoids as P-glycoprotein inhibitors in cancer chemotherapy.
Bansal T; Jaggi M; Khar RK; Talegaonkar S
J Pharm Pharm Sci; 2009; 12(1):46-78. PubMed ID: 19470292
[TBL] [Abstract][Full Text] [Related]
6. Predicting binding to p-glycoprotein by flexible receptor docking.
Dolghih E; Bryant C; Renslo AR; Jacobson MP
PLoS Comput Biol; 2011 Jun; 7(6):e1002083. PubMed ID: 21731480
[TBL] [Abstract][Full Text] [Related]
7. Inhibit or Evade Multidrug Resistance P-Glycoprotein in Cancer Treatment.
Waghray D; Zhang Q
J Med Chem; 2018 Jun; 61(12):5108-5121. PubMed ID: 29251920
[TBL] [Abstract][Full Text] [Related]
8. Psychotropic drug-drug interactions involving P-glycoprotein.
Akamine Y; Yasui-Furukori N; Ieiri I; Uno T
CNS Drugs; 2012 Nov; 26(11):959-73. PubMed ID: 23023659
[TBL] [Abstract][Full Text] [Related]
9. Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition.
Zhou SF
Xenobiotica; 2008 Jul; 38(7-8):802-32. PubMed ID: 18668431
[TBL] [Abstract][Full Text] [Related]
10. Predicting P-glycoprotein-mediated drug transport based on support vector machine and three-dimensional crystal structure of P-glycoprotein.
Bikadi Z; Hazai I; Malik D; Jemnitz K; Veres Z; Hari P; Ni Z; Loo TW; Clarke DM; Hazai E; Mao Q
PLoS One; 2011; 6(10):e25815. PubMed ID: 21991360
[TBL] [Abstract][Full Text] [Related]
11. Flavonoids as P-gp Inhibitors: A Systematic Review of SARs.
Cui J; Liu X; Chow LMC
Curr Med Chem; 2019; 26(25):4799-4831. PubMed ID: 30277144
[TBL] [Abstract][Full Text] [Related]
12. Structural and functional properties of human multidrug resistance protein 1 (MRP1/ABCC1).
He SM; Li R; Kanwar JR; Zhou SF
Curr Med Chem; 2011; 18(3):439-81. PubMed ID: 21143116
[TBL] [Abstract][Full Text] [Related]
13. Glabridin resensitizes p-glycoprotein-overexpressing multidrug-resistant cancer cells to conventional chemotherapeutic agents.
Qian J; Xia M; Liu W; Li L; Yang J; Mei Y; Meng Q; Xie Y
Eur J Pharmacol; 2019 Jun; 852():231-243. PubMed ID: 30959046
[TBL] [Abstract][Full Text] [Related]
14. Reversal of multidrug resistance by Marsdenia tenacissima and its main active ingredients polyoxypregnanes.
To KKW; Wu X; Yin C; Chai S; Yao S; Kadioglu O; Efferth T; Ye Y; Lin G
J Ethnopharmacol; 2017 May; 203():110-119. PubMed ID: 28363522
[TBL] [Abstract][Full Text] [Related]
15. Altered activity of MDR-reversing agents on KB3-1 cells transfected with Gly(185)-->Val human P-glycoprotein.
Watanabe T; Uchiyama N; Roninson IB; Cohen D; Atadja P
Int J Oncol; 2000 Sep; 17(3):579-86. PubMed ID: 10938401
[TBL] [Abstract][Full Text] [Related]
16. A Machine Learning-Based Prediction Platform for P-Glycoprotein Modulators and Its Validation by Molecular Docking.
Kadioglu O; Efferth T
Cells; 2019 Oct; 8(10):. PubMed ID: 31640190
[TBL] [Abstract][Full Text] [Related]
17. Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin.
Limtrakul P; Chearwae W; Shukla S; Phisalphong C; Ambudkar SV
Mol Cell Biochem; 2007 Feb; 296(1-2):85-95. PubMed ID: 16960658
[TBL] [Abstract][Full Text] [Related]
18. The P-glycoprotein multidrug transporter.
Fardel O; Lecureur V; Guillouzo A
Gen Pharmacol; 1996 Dec; 27(8):1283-91. PubMed ID: 9304397
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological strategies for overcoming multidrug resistance.
Nobili S; Landini I; Giglioni B; Mini E
Curr Drug Targets; 2006 Jul; 7(7):861-79. PubMed ID: 16842217
[TBL] [Abstract][Full Text] [Related]
20. Exploration of 2-((Pyridin-4-ylmethyl)amino)nicotinamide Derivatives as Potent Reversal Agents against P-Glycoprotein-Mediated Multidrug Resistance.
Qiu Q; Shi W; Li Z; Zhang B; Pan M; Cui J; Dai Y; Huang W; Qian H
J Med Chem; 2017 Apr; 60(7):2930-2943. PubMed ID: 28301155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]